Here is a brief summary of the article "Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy" published in the New England Journal of Medicine: The article discusses the use of mavacamten in adolescent patients with obstructive hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy is a disease in which the heart muscle thickens, which can lead to obstruction of blood flow from the heart. Mavacamten is a medicine that reduces the contraction of the heart muscle. The study investigated the efficacy and safety of mavacamten in this age group. The results suggest that mavacamten may improve heart function and reduce obstruction in adolescents with the condition. The study also evaluated the safety profile of the drug in this population. Detailed results and conclusions are presented in the article itself.